TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7448103
Drug: Pancuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.01 mg kg‐1
Study: 7448103
Drug: Pancuronium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.015 mg kg‐1
Study: 7448103
Drug: Pancuronium 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.02 mg kg‐1
Study: 7448103
Drug: Gallamine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallamine 0.3 mg kg‐1
Study: 31510871
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexmedetomidine 0.5 μg/kg and dexamethasone 5 mg
Study: 28371868
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy including classical needle acupuncture
Study: 28371868
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy without classical needle acupuncture
Study: 19037756
Drug: 17 mg
Normalized name: vitamin B6 17 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 mg Polaprezinc daily for 12 weeks
Study: 19037756
Drug: 34 mg
Normalized name: lysine 334 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 34 mg Polaprezinc daily for 12 weeks
Study: 19037756
Drug: 68 mg
Normalized name: pyrantel 68 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68 mg Polaprezinc daily for 12 weeks
Study: 15251273
Drug: 5 mg/16
Normalized name: nicotine 5 mg/16 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/16 h nicotine patches (Nicorette)
Study: 7936730
Drug: Analgesic upon
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic upon onset of sensation
Study: 7936730
Drug: Analgesic upon
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic upon onset of pain
Study: 2975448
Drug: 2.5, 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5, 5, 10, or 20 micrograms dose of recombinant yeast-derived hepatitis B vaccine
Study: 2975448
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms dose of plasma-derived vaccine
Study: 2975448
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms booster dose of recombinant vaccine
Study: 31838010
Drug: Ribociclib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (600 mg once daily for 3 weeks on, 1 week off) plus daily letrozole (2·5 mg/day) for 24 weeks
Study: 31838010
Drug: Chemotherapy (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days followed by weekly paclitaxel 80 mg/m2 for 12 weeks) for 24 weeks
Study: 29674370
Drug: 2 g dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g dose of cephalexin administered 40‐60 min prior to surgery
Study: 28339576
Drug: Post-treatment e-cigarette
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment e-cigarette users
Study: 16517274
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (Control)
Study: 14753593
Drug: Monophasic injection
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic injection protocol (123 mL at 2.5 mL/s)
Study: 14753593
Drug: Biphasic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic injection protocol (123 mL, 60 mL at 1.5 mL/s and then 63 mL at 2.5 mL/s)
Study: 14753593
Drug: Sigmoid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sigmoid injection protocol (0.6 mL/s ending at 2.5 mL/s)
Study: 1600772
Drug: Greatest response-invoking
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Greatest response-invoking agent (specific agent not mentioned)
Study: 1600772
Drug: Least response-invoking
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Least response-invoking agent (specific agent not mentioned)
Study: 25253665
Drug: LIPO-5 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIPO-5 (250 μg)
Study: 25253665
Drug: ALVAC-HIV (vCP1452)
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV (vCP1452) + LIPO-5 (250, 750, and 2,500 μg)
Study: 2952396
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of vitamin C daily
Study: 20303119
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg solifenacin once daily
Study: 20303119
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oxybutynin immediate release 3 times daily
Study: 15726875
Drug: Benfotiamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfotiamine (50 mg tablets, four times daily for three weeks)
Study: 2567670
Drug: Metoprolol (M,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (M, 100 mg)
Study: 2567670
Drug: Pindolol (P,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (P, 10 mg)
Study: 23246919
Drug: Previous hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous hormone therapy (HT) use
Study: 27387522
Drug: Adaptive servo-ventilation
Normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adaptive servo-ventilation (ASV) therapy
Study: 23250911
Drug: Non-ASV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ASV treatment (control group)
Study: 21955700
Drug: ASV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASV therapy
Study: 2882773
Drug: temelastine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: temelastine 100 mg
Study: 26712942
Drug: Topical DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical DFMO applied twice daily
Study: 26712942
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac applied daily
Study: 24823430
Drug: Cognitive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive group therapy combined with pharmacotherapy
Study: 24823430
Drug: Happiness training
Normalized name: Happy Cappy
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Happiness training combined with pharmacotherapy
Study: 22192331
Drug: Pharmacotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy only
Study: 20508081
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro protamine suspension (ILPS) 0.6 U/kg
Study: 20508081
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 0.6 U/kg
Study: 15802149
Drug: Home cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home cancer healthcare program (chemotherapy)
Study: 22124104
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus surgery
Study: 7358211
Drug: Piracetam (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (4.8 g per day for 4 days and 7.2 g on the 5th day)
Study: 31668556
Drug: Wet cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet cupping therapy (WCT) applied once a month for 12 months (Group 2)
Study: 25557762
Drug: interleukin 2
Normalized name: Recombinant interleukin 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: interleukin 2 receptor antagonists (IL‐2RA)
Study: 22080012
Drug: Normal vaccination
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal vaccination (simplified vaccination + second dose of ND‐IB, H120, and AI)
Study: 16807618
Drug: Eprosartan 600
Normalized name: eprosartan 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 600 mg tablet once daily for 10 weeks
Study: 8262292
Drug: Amox‐CA (Augmentin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amox‐CA (Augmentin) 1.2 g intravenous injection, 1 hour after delivery
Study: 18390558
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation radiation therapy (2.4 Gy/fr)
Study: 18390558
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation radiation therapy (2 Gy/fr)
Study: 15988102
Drug: cilostazol +
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cilostazol + aspirin (C group)
Study: 15988102
Drug: ticlopidine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ticlopidine + aspirin (T group)
Study: 10774681
Drug: Combination regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimens of artemether/pyrimethamine (1‐, 2‐ and 3‐day regimens)
Study: 1649863
Drug: Atenolol (antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (antihypertensive drug treatment group)
Study: 6858934
Drug: Pirmenol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirmenol (50 mg priming bolus over 2 minutes, followed by 2.5 mg/min for 1 hour, and 0.25 mg/min maintenance infusion)
Study: 27957632
Drug: Antiepileptic drug
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drug (AED) treatment
Study: 27957632
Drug: Non-AED treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-AED treatment (Control)
Study: 27957632
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis of patients with subcortical calcifications (AED treatment)
Study: 26821625
Drug: Chlorthalidone, 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone, 6.25 mg daily
Study: 26821625
Drug: HCTZ, 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ, 12.5 mg daily
Study: 26821625
Drug: HCTZ-CR, 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ-CR, 12.5 mg daily
Study: 23405799
Drug: Yangjing Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangjing Capsule (5 pills, tid) plus low-dose tadalafil (5 mg, qd, 1 h before bedtime)
Study: 23405799
Drug: Oral ephedrine
Normalized name: ephedrine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ephedrine (25 mg before bedtime)
Study: 17503670
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg Suc-HSA (single dose)
Study: 17503670
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg Suc-HSA (single dose)
Study: 17503670
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg Suc-HSA (multiple doses)
Study: 12470517
Drug: 585 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 585 nm laser treatment at subpurpura energy level
Study: 12470517
Drug: Second treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second treatment with 585 nm laser 2 weeks later
Study: 9638854
Drug: Low-dose ATG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ATG (total dose 484 +/- 110 mg, 0.75 mg/kg per day)
Study: 9638854
Drug: Low-dose OKT3
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OKT3 (total dose 32 +/- 4 mg, 0.05 mg/kg per day)
Study: 9638854
Drug: Low-dose OKT3
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OKT3
Study: 28162127
Drug: Monthly food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly food voucher of $US 40
Study: 28162127
Drug: Monthly food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly food voucher of $US 40 plus training on health and nutrition
Study: 25119510
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection into the long posterior sacroiliac ligament
Study: 25119510
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection on the contralateral side
Study: 22085683
Drug: Acupuncture as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture as an adjunct to pharmacotherapy
Study: 9715427
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg for the first week, 50 mg for the second week, and 75 mg nightly thereafter for 12 weeks
Study: 2737169
Drug: Sip-feed supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sip-feed supplements
Study: 2737169
Drug: Non-compliant patients
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-compliant patients (who failed to receive supplements)
Study: 22894624
Drug: AMR101 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR101 4 g/day
Study: 22894624
Drug: AMR101 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR101 2 g/day
Study: 21683321
Drug: AMR101 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR101 4 g/day (baseline TG >750 mg/dl)
Study: 21683321
Drug: AMR101 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMR101 2 g/day (baseline TG >750 mg/dl)
Study: 19390542
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg/HCTZ 12.5 mg (titrated to losartan 100 mg/HCTZ 12.5 mg at 4 weeks and losartan 100 mg/HCTZ 25 mg at 8 weeks)
Study: 19390542
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg/HCTZ 12.5 mg
Study: 19390542
Drug: losartan/HCTZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan/HCTZ combination therapy
Study: 15572179
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 and 2 mg on two successive days)
Study: 27600795
Drug: Omacor® 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor® 4 g/day
Study: 27600795
Drug: Omacor® 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor® 2 g/day
Study: 26068602
Drug: UFT/LV (tegafur-uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/LV (tegafur-uracil with leucovorin) administered at 300 mg/m²/day with 75 mg/day for 5 courses (5 weeks each)
Study: 21804100
Drug: Two fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two fixed-dose combination tablets (ibuprofen 400 mg/paracetamol 1000 mg)
Study: 21804100
Drug: One fixed-dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One fixed-dose combination tablet (ibuprofen 200 mg/paracetamol 500 mg)
Study: 21804100
Drug: One combination
Normalized name: urine glucose-acetone combination test strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: One combination tablet (ibuprofen 200 mg/paracetamol 500 mg)
Study: 21804100
Drug: Two combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two combination tablets (ibuprofen 400 mg/paracetamol 1000 mg)
Study: 12962764
Drug: Dual-drug therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-drug therapy (tacrolimus and corticosteroids)
Study: 12962764
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (tacrolimus, azathioprine, and corticosteroids)
Study: 8621832
Drug: Combination UVB/UVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination UVB/UVA phototherapy
Study: 6530538
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (50 mmol daily)
Study: 6530538
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (300 mmol daily)
Study: 6530538
Drug: Intravenous frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous frusemide administration
Study: 30659039
Drug: Daily intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intake of refined wheat bread enriched with 6 g of wheat germ
Study: 25205802
Drug: Pooled cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled cohort (TAVR, n=220; standard therapy, n=229)
Study: 22828688
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine (dexmedetomidine group)
Study: 22828688
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine 0.5% plus 5 μg dexmedetomidine and 25 μg fentanyl (dexmedetomidine= group)
Study: 22828688
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine 0.5% (control group)
Study: 22987572
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg rosuvastatin
Study: 9651560
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pravastatin
Study: 12486428
Drug: rosuvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (5 mg and 10 mg)
Study: 8133086
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with zidovudine and didanosine (ddI)
Study: 241115
Drug: Sucrose-containing iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose-containing iron medicines
Study: 241115
Drug: 50% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% aqueous sucrose solution
Study: 241115
Drug: Iron medicines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron medicines with sorbitol
Study: 27918724
Drug: telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: telotristat ethyl 250 mg
Study: 27918724
Drug: telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: telotristat ethyl 500 mg
Study: 27918724
Drug: telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: telotristat ethyl 250 mg and 500 mg
Study: 22074836
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, only observation)
Study: 15633321
Drug: 3% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% potassium oxalate gel
Study: 10728365
Drug: 2 I.U.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 I.U. of recombinant human growth hormone (GH) for 3 months
Study: 8957033
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive drugs (n = 35)
Study: 3575131
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg i.m. of Phytonadione (Konakion, Roche) administered on the initial day of GFD
Study: 3575131
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin K administration (Control group)
Study: 26733351
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus (one ComProbi capsule containing L. rhamnosus a day)
Study: 26733351
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule of placebo a day)
Study: 25454870
Drug: Vaccine, IL-2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine, IL-2, GM-CSF and rhGH (n=3)
Study: 25454870
Drug: Vaccine alone
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine alone (n=4)
Study: 19201650
Drug: Erlotinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib (150 mg daily) and bevacizumab (15 mg/kg every 3 weeks)
Study: 11269613
Drug: Beef protein
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beef protein (43 g for women and 50 g for men daily)
Study: 9464712
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (60 g daily containing 40 g of isolated soy protein)
Study: 9464712
Drug: Placebo (casein,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (casein, 60 g daily)
Study: 794897
Drug: Amitriptyline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (150 mg daily)
Study: 794897
Drug: L-tryptophan (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (8 g daily)
Study: 27539689
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy
Study: 30537411
Drug: Exercise dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise dose (kilocalories per session)
Study: 23558043
Drug: ivabradine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine (5 mg twice daily)
Study: 23558043
Drug: ranolazine (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranolazine (375 mg twice daily)
Study: 22010346
Drug: Tangshen Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangshen Formula + Conventional western medicine
Study: 17557758
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg)
Study: 14999637
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (800 mg every day)
Study: 14999637
Drug: Oxandrolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (10 mg twice per day)
Study: 7985255
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg terbutaline
Study: 7985255
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg terbutaline
Study: 7985255
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg terbutaline
Study: 8491302
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of terbutaline (2, 4, 6 mg)
Study: 6366126
Drug: Any oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any oral intestine decontamination regimen
Study: 27005498
Drug: Low lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lactose milk powder feeding in treatment group (64 cases)